On October 1, 2025 Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Jechobio") reported it has made another breakthrough in independently developed innovative drugs, offering a tribute to the National Day through scientific achievement (Press release, Jecho Laboratories, OCT 1, 2025, View Source [SID1234656380]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jechobio has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA), officially approving the clinical trial of JL19001 injection for the treatment of non-muscle-invasive bladder cancer (NMIBC).

Looking ahead, Jechobio will continue to uphold its innovation-driven mission, accelerate its drug development efforts, and contribute to advancing human health and well-being worldwide.

About JL19001 Injection

JL19001 injection is a Class I innovative drug jointly developed by Jecho laboratories, Inc. (USA) and Jecho Biopharmaceuticals Co., Ltd. It is a fusion protein composed of recombinant human serum albumin (HSA) and an IL-15Rα/IL-15 complex, designed to activate NK cells and CD8⁺ T cells, enhancing both innate and adaptive immune responses.

When used in combination with Bacillus Calmette–Guérin (BCG), JL19001 is intended to treat non-muscle-invasive bladder cancer (NMIBC) by helping avoid bladder removal surgery, thus improving patient survival rates and quality of life.

On October 1, 2025 Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, reported that it will present and host institutional investor meetings at the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4, 2025 at the Lotte New York Palace Hotel in New York, NY (Press release, Immix Biopharma, OCT 1, 2025, View Source [SID1234656379]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Piper Sandler representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

On October 1, 2025 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, reported the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately (Press release, Immatics, OCT 1, 2025, View Source [SID1234656378]). Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos Therapeutics, a Novartis company, where he served as CFO. He will succeed Immatics’ current CFO, Arnd Christ.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to welcome Venkat to Immatics as an accomplished and passionate biopharmaceutical leader. His extensive experience will be instrumental in enabling us to continue to advance our PRAME franchise as well as rapidly move our PRAME cell therapy, anzu-cel, toward commercialization and to patients with a significant unmet medical need," said Harpreet Singh, Ph.D., Chief Executive Officer and Co-Founder of Immatics. "I would also like to extend our gratitude to Arnd Christ for his financial leadership and tremendous contributions that have brought Immatics to where it stands today. On behalf of the entire team, I wish him all the best in his future endeavors."

"This is a pivotal moment to join Immatics as the company advances toward its first commercial launch and works to bring its innovative PRAME cell therapy, anzu-cel, to patients with metastatic melanoma," said Venkat Ramanan, Ph.D., Chief Financial Officer of Immatics. "I look forward to collaborating closely with the team during this dynamic stage of growth and supporting the transition to a commercial-stage organization. Together, we will further strengthen Immatics’ position as the global leader in precision targeting of PRAME, united by our commitment to making a meaningful impact on the lives of patients with cancer."

Dr. Ramanan brings more than 25 years of experience and leadership in finance, strategy and operations across large and small biopharmaceutical companies, with a proven track record of leading companies through periods of successful transformation and growth. He joins Immatics from Anthos Therapeutics, a clinical-stage biotechnology company acquired by Novartis in April 2025, where he served as CFO. Previously, he was CFO at Turnstone Biologics, where he led the company’s transition from a private to public company through its IPO. Earlier, as Senior Vice President Finance at Seagen, he oversaw the finance department enabling multiple product launches, global expansion and strategic transactions. He also held senior finance and business leadership roles at Gilead Sciences and Amgen. He began his career in the biopharmaceutical industry as a consultant with ZS Associates. Dr. Ramanan holds a Ph.D. in Engineering Mechanics from The Ohio State University.

On October 1, 2025 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, taking place October 7-10, 2025 (Press release, CRISPR Therapeutics, OCT 1, 2025, View Source [SID1234656376]). The presentation will introduce the Company’s novel SyNTase gene editing technology and highlight its application in single-dose in vivo gene correction to treat Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disorder.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform. SyNTase editors represent a significant advance over currently described prime editing systems by combining compact Cas9 proteins with a novel class of engineered polymerases. Together, these components enable gene editing with greater efficiency and precision, while also supporting scalable manufacturing.

Using AI-guided structural modeling and large-scale screening, the polymerase was optimized to support gene correction activity based on synthetic nucleotide templates. When integrated with Cas9, SyNTase editors can utilize engineered templates with improved serum stability, enabling higher target correction efficiency.

The abstract describes that SyNTase editing produces high levels of editing (up to 95%) in SERPINA1-E342K human hepatocyte cell models without any detectable (<0.5%) off-target effects. In a humanized mouse model, SyNTase editing components encapsulated in a lipid nanoparticle (LNP) enabled highly efficient, specific, and potentially curative gene correction with a single intravenous (IV) dose (≤0.5 mg/kg) with a well-tolerated safety profile. In a custom humanized rat model of AATD, SyNTase editing achieved potent gene correction of the E342 mutation with >70% mRNA correction and >3-fold total serum AAT upregulation, exceeding the established clinically protective threshold. Together, these data provide proof-of-concept for a potentially best-in-class therapeutic modality to address the underlying cause of AATD and support SyNTase editing as a promising platform for the treatment of many monogenic disorders. Additional results beyond those included in the abstract will be presented at the conference.

Presentation Details
Title: Single-dose in vivo gene correction of AATD via LNP-delivered SyNTase editors
Abstract Number: OR096
Session Type: Oral Presentation
Session Title: SESSION 12c: Gene Editing III: Technology & applications
Session Date and Time: Friday, October 10, 2025, 11:00 a.m. – 1:00 p.m. CEST

The accepted abstract is available online on the ESGCT website for congress registrants. Any updated data, new graphics, and follow-up information to be presented during the oral presentation sessions is embargoed until 8:00 a.m. CEST on the day of the presentation. A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

On October 1, 2025 Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, reported that the European Society of Cell and Gene Therapy (ESGCT) has selected a Circio abstract for poster presentation at its annual meeting 2025 (Press release, Circio, OCT 1, 2025, https://www.circio.com/en/circio-to-present-comprehensive-circvec-aav-in-vivo-data-package-at-esgct-2025/ [SID1234656375]). The presentation will detail how Circio is enhancing gene and cell therapy using circVec, its circular RNA vector expression technology. Specifically, Circio will summarize recent in vivo results demonstrating significant advantages of its circVec-AAV platform over conventional AAVs in heart and other tissues.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Circio´s most recent in vivo results continue to demonstrate circVec´s strong potential as a novel expression system for enhanced gene and cell therapy. The prestigious ESGCT annual meeting provides an excellent opportunity for us to showcase our latest pre-clinical data to a wide industry and academic audience," said Dr. Thomas B. Hansen, CTO of Circio. "At this year´s conference, we will present the major advances we have made to enhance conventional AAV gene therapy using the circVec platform, showing statistically significant increases in expression in multiple tissues for several circVec-AAV variants."

Title of presentation:
CircVec: Enhancing gene and cell therapy using circular RNA vector expression technology (poster no. 1041)

Presenter:
CTO Dr. Thomas B Hansen & CSO Dr. Victor Levitsky

Time:
14:00hrs CEST, 8 October 2025

Location:
Fibes, Seville, Spain